Comment on “Efficacy of Tongdu Tiaoshen Acupuncture Combined with Local Pelvic Floor Acupoints for Pelvic Floor Myofascial Pain Syndrome: A Randomized Controlled Trial Protocol” [Letter] Authors: Minmin Zhang, Wenqi Zhang, Ruijie Ma Published: 2026 Dear editor I read with great interest the study protocol by Ye et al1 recently published in the Journal of Pain Research, entitled “Efficacy of Tongdu Tiaoshen Acupuncture Combined with Local Pelvic Floor Acupoints for Pelvic Floor Myofascial Pain Syndrome: A Randomized Controlled Trial Protocol”, which aims to evaluate acupuncture versus combined electromyographic biofeedback and neuromuscular electrical stimulation (EMG-BF+NMES) for myofascial pelvic pain syndrome (MPPS). The authors should be commended for tackling a clinically challenging condition with a rigorous multicentre randomized design and a comprehensive array of outcome measures. The following suggestions aim to further enhance the interpretability of the trial results. First, the primary outcome collapses resting pain and evoked trigger‑point tenderness into a single Visual Analog Scale (VAS), which might hide the differences between the two in terms of clinical significance. In the flowchart, the primary endpoint monolithically as “Pain intensity and pelvic floor myofascial tenderness were assessed using the Visual Analog Scale”. In MPPS, spontaneous pain at rest and evoked tenderness upon palpation of a trigger point are neurologically different phenomena and may respond differently to treatment.2 Previous pelvic‑pain trials have successfully distinguished these two dimensions, demonstrating that a pressure‑standardised tenderness VAS can capture intervention effects with greater sensitivity than a global intensity score.3 Therefore, it is recommended to set the induced tenderness VAS obtained under blinded, standardized procedures (measured at preset hyperalgesia points) as the primary outcome, while using the average spontaneous pelvic pain intensity over the past week as a key secondary endpoint, consistent with IMMPACT recommendations.4 Second, including “immediately after the first intervention (T1)” as a primary efficacy time point may compromise the validity of the conclusions. Table 1 lists T1 among the scheduled assessments for the main VAS outcome. Yet both acupuncture and EMG-BF+NMES require a series of sessions to achieve stable clinical pain relief; single‑session effects are heavily influenced by expectation, conditioning, and the inability to blind practitioners and participants.5,6 If this already quite variable data is used to support the main efficacy conclusions, it could lead to overinterpreting early nonspecific responses and weaken the credibility of subsequent group comparisons. It would be prudent for the investigators to explicitly pre‑specify that the primary confirmatory analysis will rely on the end‑of‑treatment (T4) and 3‑month follow‑up (T5) data, while data from T1 are retained solely for exploratory responder‑characterisation and safety surveillance. These suggestions aim to strengthen an already well-planned study. I hope the authors find them constructive and wish them every success in completing this important trial. Disclosure The authors declare no conflicts of interest in this communication. References